Urinary Tract Infection (UTI) Treatment Market Size, Share, and Growth Forecast for 2025 - 2032

Urinary Tract Infection (UTI) Treatment Market Size and Trends

The global urinary tract infection treatment market size is anticipated to rise from US$ 10.37 Bn in 2025 to US$ 15.08 Bn by 2032. It is projected to witness a CAGR of 5.5% from 2025 to 2032.

The rising prevalence of urinary tract infections is fueled by antibiotic resistance, aging populations, and increased awareness of symptoms, leading to higher diagnosis and treatment rates across the world.

• According to the World Health Organization (WHO), antimicrobial resistance is a major global health threat, making common infections, including UTIs, harder to treat.
• Based on the 2023 study by the CDC reported that over 2.8 million drug-resistant infections occur annually in the U.S., with Escherichia coli being the most common cause of UTIs.

Companies like GSK, Pfizer, and Merck are investing in new therapies and diagnostic tools to enhance treatment efficacy in the expanding global UTI treatment market due to increased healthcare expenditure.

The rising geriatric population, which is expected to reach 1.5 billion by 2050 based on the recording by the United Nations, further increases UTI cases, as older adults are more susceptible. 

Key Highlights of the Urinary Tract Infection (UTI) Treatment Market

• The rise in antibiotic resistance necessitates the creation of innovative treatments and medications.
• Research and development investments are crucial in driving innovation in UTI diagnostic technologies. 
• Healthcare expenditure growth is enhancing access to advanced UTI therapies in North America.
• The increasing awareness of UTI symptoms leads to an increase in diagnosis and treatment in Asia Pacific.
• Hospital Pharmacies dominate owing to their vital role hospitals play in treating severe and complicated UTIs, holding a 52.3% market share in 2025.

Global Market Attributes	Key Insights
Urinary Tract Infection (UTI) Treatment Market Size (2025E)	US$ 10.37 Bn
Market Value Forecast (2032F)	US$ 15.08 Bn
Projected Growth (CAGR 2025 to 2032)	5.5%
Historical Market Growth (CAGR 2019 to 2024)	4.9%

Historical Growth and Course Ahead

Prevalence of Diabetes and Kidney Stones Gained Impetus Amid the Pandemic

The global UTI treatment industry experienced a CAGR of 4.9% from 2019 to 2024. Following the pandemic, the market trends for UTI treatments are increasingly influenced by the prevalence of kidney stones and diabetes.

• In 2024, nearly 463 million individuals worldwide are living with diabetes. This number is projected to rise to 643 million by 2030 and may reach 700 million by 2045.

People with diabetes are at a higher risk of urinary tract infections due to elevated sugar levels in their urine, which create an ideal environment for bacteria to thrive.

• Diabetic patients are 38% more likely to experience UTIs, with 63.16% of affected individuals being females and 36.84% being males.
• Additionally, around 11% of the population has kidney stones, also known as nephrolithiasis or urolithiasis, with an overall prevalence rate of 11.2%. The risk of developing urolithiasis is 1.8 times greater in males than in females.

Several pharma companies are estimated to invest in the research and development of drugs and therapeutics to cater to the growing population of patients.

Research and Development of Combination Drugs to Boost Sales through 2032

From 2025 to 2032, the global market for urinary tract infection treatments is projected to report a CAGR of 5.5%, according to studies by Persistence Market Research. The introduction of novel combination medications has significantly advanced the market for complex UTIs. In 2025, Penicillin and combination drugs for UTI treatments are projected to cater to the market share of 22.7% with innovative research and developments.

Adults suffering from complex UTIs can now be treated with Merck & Co.'s Recarbrio, an antibiotic medication. Additionally, Pfizer has launched an innovative combination antibiotic called Zavicefta in the UK and Germany.

The French pharmaceutical company Exblifep is also developing a combination of enmetazobactam and cefepime, highlighting the expanding research pipeline for combination medications. Furthermore, researchers at California Polytechnic State University are working on a new class of medicines for UTIs that target bacterial iron uptake.

These new medications are crucial for combating antibiotic resistance and providing targeted therapeutic options for both straightforward and complex urinary tract infections.

Market Dynamics

Growth Drivers

Rising Prevalence of Drug-resistant UTIs Spurs Research in Precision Medicine 

The emergence of bacteria resistant to antibiotics is posing a serious threat to the market for treatments for urinary tract infections. Antibiotic-resistant bacteria, particularly those that cause UTIs, have emerged due to the extensive use of antibiotics. The World Health Organization (WHO) has classified antimicrobial resistance as one of the top global health threats, with UTIs being among the most common bacterial infections affected.

• According to the U.S. Centers for Disease Control and Prevention (CDC), over 2.8 million antibiotic-resistant infections occur annually in the U.S., leading to more than 35,000 deaths.
• The Escherichia coli (E. coli) strain, responsible for 80 to 90% of UTIs, has shown increasing resistance to fluoroquinolones and cephalosporins.

This alarming trend has fueled investments in alternative therapies, such as bacteriophage therapy, immune-boosting treatments, and precision medicine approaches.

• In April 2024, GSK and Pfizer announced joint efforts to develop next-generation antibiotics targeting drug-resistant UTI strains.

Additionally, regulatory bodies, including the FDA and EMA, are prioritizing fast-track approvals for novel UTI therapies to combat rising resistance rates.

Market Restraining Factors

Rising Self-prescription of Antibiotics Escalates Healthcare Costs and Resistance Risks

The trend of self-medication and the widespread availability of over-the-counter (OTC) antibiotics challenges the urinary tract infection treatment market.

• According to the World Health Organization, nearly 50% of antibiotics are prescribed or used inappropriately, contributing to the rise of antibiotic-resistant bacteria.
• In 2023, studies reported that 75% of UTI patients in developing nations purchased antibiotics without a prescription, increasing the risk of resistance.

Silent UTIs, which show no symptoms but involve bacterial colonization, further complicate diagnosis and treatment. Research by the CDC found that 15 to 20% of UTI cases are asymptomatic, leading to unnecessary antibiotic use.

To combat these issues, healthcare authorities in April 2024 launched initiatives promoting rapid diagnostic tools, such as PCR-based urine tests, to differentiate between bacterial colonization and active infection.

Additionally, governments worldwide, including the European Medicines Agency (EMA), are tightening OTC antibiotic regulations to curb misuse and reduce resistance rates.

Key Market Opportunities

Point-of-care Testing Revolutionizing UTI Diagnosis with Quicker and More Accurate Detection

Advancements in diagnostic technologies are transforming the market for urinary tract infection treatments by enabling faster and more accurate identification of UTI-causing organisms. Point-of-care (POC) testing methods, including biosensors and molecular assays, facilitate quick diagnosis, leading to more targeted therapies and reduced rates of recurrence.

Leading companies in the healthcare sector are envisioned to introduce novel testing tools and therapies to advance in the research sector for UTI treatments. For instance,

• In November 2023, Becton Dickinson (BD) launched a high-sensitivity POC molecular assay that reduces the diagnosis time from days to just hours.
• Additionally, in October 2023, Siemens Healthineers introduced a rapid UTI detection test utilizing AI-powered biosensors for real-time diagnosis.

The growing demand for personalized medicine underscores the need for rapid diagnostic investments to enhance patient outcomes and alleviate the burdens on healthcare systems.

Urinary Tract Infection (UTI) Treatment Market Insights and Trends

Drug Class Insights

Rising Demand for Quinolones Pushed by Low Resistance Rates and Effectiveness against UTIs

In 2025, the quinolones segment dominated the UTI therapeutics market, accounting for 43.2% of the market share. Quinolones, including antibiotics like ciprofloxacin and levofloxacin, are widely used in treating urinary tract infections due to their broad-spectrum activity against various bacteria. They are often prescribed as first-line treatments for uncomplicated UTIs due to their effectiveness, low resistance rates, and established clinical usage.

Nitrofurans, particularly Nitrofurantoin, are expected to be the fastest-growing subsegment due to their unique mechanism of action targeting urinary tract bacteria. This is due to their broad spectrum of activity against both gram-positive and gram-negative bacteria, particularly their effectiveness against uropathogenic Escherichia coli (UPEC).

The quinolones segment's strong market presence is supported by their high bioavailability and ability to achieve high concentrations in urinary tract tissues.

Application Insights

Rising Cases of Complicated UTIs Bolster Demand for Novel Therapeutics Amid Antibiotic Resistance

Uncomplicated urinary tract infections will account for 68.4% of the market in 2025, owing to their ease of diagnosis and treatment with short-course medicines. However, Complicated UTIs, which account for 31.6%, are on the rise due to an increase in cases connected to diabetes, renal illness, and compromised immune systems.

Complex UTIs now require more sophisticated treatments due to the rising incidence of bacteria resistant to antibiotics.

• In October 2023, GSK launched a new oral antibiotic for uncomplicated UTIs, reducing treatment time by 30%.
• In November 2023, Merck & Co. expanded its IV therapy portfolio, offering better solutions for complicated infections.

Pharmaceutical companies are prioritizing research and developing personalized treatments for UTI therapeutics to improve patient outcomes and reduce recurrence rates due to increased chronic illness risk.

Regional Insights and Trends

Strong Pharmaceutical Research and Awareness to Propel North America's Growth

North America's UTI treatment market is set to dominate globally, holding a 39.2% market share in 2025. This growth is fueled by advanced healthcare infrastructure, high awareness, and strong research initiatives. The CAGR from 2025 to 2032 is projected at 4.8%, driven by continuous innovations in UTI treatments.

The U.S. leads the region with 82% of the market, supported by major pharmaceutical advancements and government-backed healthcare initiatives. Canada is the fastest-growing market due to rising healthcare investments. Recent advancements in the healthcare sector are shaping the market in North America. For instance,

• In October 2023, Pfizer expanded its UTI antibiotic pipeline to address drug-resistant infections.

Additionally, UroGen Pharma announced in October 2024 that the FDA accepted its New Drug Application (NDA) for UGN-102, a new non-surgical treatment for low-grade UTI. Such innovations continue to drive market expansion in North America.

Rising Elderly UTI Cases Fuel Demand for Innovative Pain Management Solutions in Europe

Europe is set to hold a 22.6% share of the global UTI pain medication market in 2025, driven by its aging population and advanced healthcare system. The increasing incidence of UTIs among the elderly, due to age-related bladder changes and weakened immune systems, is expected to fuel the demand for effective pain relief solutions in Europe.

• According to the National Institute on Aging (NIA), nearly 50% of older adults experience urinary incontinence, a condition often linked to recurrent UTIs.
• A study published in PMC highlights that UTI-related hospitalizations among seniors have risen by 32% over the past decade.

Recognizing the growing concern, pharmaceutical companies in Europe are investing in research and development for elderly-specific UTI treatments. For instance,

• In November 2023, Sanofi expanded its UTI research program, focusing on faster-acting analgesics for elderly patients.
• Similarly, in October 2023, GlaxoSmithKline (GSK) launched a new UTI pain relief drug aimed at improving symptom management for seniors.  

Improved Healthcare Access and Diagnostics Fuel UTI Treatment Growth in Asia Pacific

Asia Pacific is expected to hold a 19.6% share of the global UTI treatment market in 2025, driven by enhanced healthcare access, raising awareness, and improved diagnostic rates. The region is witnessing a significant increase in UTI cases, in China, India, and Japan, due to aging populations and evolving lifestyles.

• According to World Health Organization, 60% of women in the Asia Pacific will experience a UTI at some point in their lives, making early detection and effective treatment crucial.

Pharmaceutical companies are capitalizing on this demand with innovative solutions. For instance,

• In October 2023, Cipla launched a rapid UTI detection kit in India, facilitating early diagnosis and treatment. Meanwhile, in November 2023, Takeda Pharmaceuticals introduced a new oral antibiotic in Japan, improving treatment options for drug-resistant UTIs.

With a projected CAGR of 5.6% from 2025 to 2032, Asia Pacific remains a key growth region for UTI therapeutics and diagnostics.

Urinary Tract Infection (UTI) Treatment Market Competitive Landscape

Companies are seeking strategic alliances and collaborations to expand their skills and reach in the ever-changing urinary tract infection treatment industry. To concentrate on their core competencies, some are opting to sell up particular company segments.

Key market participants are expected to fund research and development initiatives in the healthcare industry in order to preserve and strengthen their competitive advantage. Advancement of treatment alternatives and adaptation to changing patient demands depend on this dedication to innovation and improvement.

Key Industry Developments

• In July 2024, Star Health Insurance launched cashless home healthcare services in 50 Indian cities, partnering with providers like Care24, Portea, CallHealth, and Athulya Homecare to provide accessible, affordable healthcare.
• In April 2024, Utility Therapeutics won FDA approval for Pivya, an oral antibiotic targeting penicillin binding protein-2 in gram-negative bacteria, a first-line therapy for complicated urinary tract infections. 
• In April 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved cefepime/enmetazobactam, a combined antibiotic, for treating urinary tract infections and pneumonia during hospital stays, with safety and effectiveness under close review.
• In February 2024, Allecra Therapeutics granted a five-year marketing exclusivity extension for Exblifep, a cefepime/enmetazobactam used to treat complicated urinary tract infections, including pyelonephritis, in patients aged 18 and older.

Urinary Tract Infection (UTI) Treatment Market Report Scope

Report Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn/Mn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Drug Class Application Distribution Channel Region
Competitive Analysis	Pfizer Bayer AG Almirall SA GlaxoSmithKline Pharmaceuticals Ltd. Merck & Co., Inc. Bristol-Myers Squibb Shionogi & Co., Ltd Cipla Inc.
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Urinary Tract Infection (UTI) Treatment Market Segmentation

By Drug Class

• Penicillin & Combinations
• Quinolones
• Cephalosporin
• Aminoglycoside Antibiotics
• Sulphonamides (Sulfamethoxazole, Trimethoprim)
• Azoles and Amphotericin B
• Tetracycline (Doxycycline)
• Nitrofurans (Nitrofurantoin)
• Others

By Application

• Complicated Urinary Tract Infection
• Uncomplicated Urinary Tract Infection

By Distribution Channel

• Hospital Pharmacies
• Gynecology and Urology Clinics
• Drug Stores
• Retail Pharmacies
• Online Drug Stores

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

To know more about delivery timeline for this report Contact Sales

About Author